TY - JOUR A1 - Hartrampf, Philipp E. A1 - Petritsch, Bernhard A1 - Buck, Andreas K. A1 - Serfling, Sebastian E. T1 - Pitfalls in PSMA-PET/CT: Intensive bone-marrow uptake in a case with polycythaemia vera JF - European Journal of Nuclear Medicine and Molecular Imaging N2 - No abstract available. KW - bone-marrow Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-235608 SN - 1619-7070 VL - 48 ER - TY - JOUR A1 - Soehnlein, Oliver A1 - Drechsler, Maik A1 - Döring, Yvonne A1 - Lievens, Dirk A1 - Hartwig, Helene A1 - Kemmerich, Klaus A1 - Ortega-Gómez, Almudena A1 - Mandl, Manuela A1 - Vijayan, Santosh A1 - Projahn, Delia A1 - Garlichs, Christoph D. A1 - Koenen, Rory R. A1 - Hristov, Mihail A1 - Lutgens, Esther A1 - Zernecke, Alma A1 - Weber, Christian T1 - Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes JF - EMBO Molecular Medicine N2 - We used a novel approach of cytostatically induced leucocyte depletion and subsequent reconstitution with leucocytes deprived of classical \((inflammatory/Gr1^{hi})\) or non-classical \((resident/Gr1^{lo})\) monocytes to dissect their differential role in atheroprogression under high-fat diet (HFD). Apolipoprotein E-deficient \((Apoe^{-/-})\) mice lacking classical but not non-classical monocytes displayed reduced lesion size and macrophage and apoptotic cell content. Conversely, HFD induced a selective expansion of classical monocytes in blood and bone marrow. Increased CXCL1 levels accompanied by higher expression of its receptor CXCR2 on classical monocytes and inhibition of monocytosis by CXCL1-neutralization indicated a preferential role for the CXCL1/CXCR2 axis in mobilizing classical monocytes during hypercholesterolemia. Studies correlating circulating and lesional classical monocytes in gene-deficient \(Apoe^{-/-}\) mice, adoptive transfer of gene-deficient cells and pharmacological modulation during intravital microscopy of the carotid artery revealed a crucial function of CCR1 and CCR5 but not CCR2 or \(CX_3CR1\) in classical monocyte recruitment to atherosclerotic vessels. Collectively, these data establish the impact of classical monocytes on atheroprogression, identify a sequential role of CXCL1 in their mobilization and CCR1/CCR5 in their recruitment. KW - hypercholeterolemia KW - CCR2 KW - atherosclerosis KW - chemokine KW - accumulation KW - subsets KW - inflammatory sites KW - fractalkine KW - marcophages KW - mobilization KW - monocyte KW - recruitment KW - bone-marrow KW - atheriosclerotic lesions KW - hyperlipedemic mice Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122204 SN - 1757-4676 VL - 5 ER - TY - JOUR A1 - Giordano, Rosaria A1 - Canesi, Margherita A1 - Isalberti, Maurizio A1 - Isaias, Ioannis Ugo A1 - Montemurro, Tiziana A1 - Viganò, Mariele A1 - Montelatici, Elisa A1 - Boldrin, Valentina A1 - Benti, Riccardo A1 - Cortelezzi, Agostino A1 - Fracchiolla, Nicola A1 - Lazzari, Lorenza A1 - Pezzoli, Gianni T1 - Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study JF - Journal of Translational Medicine N2 - Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to date available. Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered to the affected brain regions of PSP patients where they can exert their beneficial effects through different mechanisms including the secretion of neurotrophic factors. Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP with MSC delivered via intra-arterial injection. Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression. The study has been designed to test the safety of this " first-in-man" approach and to preliminarily explore its efficacy by excluding the placebo effect. Trial registration: NCT01824121 KW - Parkinson's disease KW - cellular therapy KW - deep brain-stimulation KW - bone-marrow KW - transplantation KW - receptor tyrosine kinase KW - Richardson-Olszewski-Syndrome KW - multiple system atrophy KW - advanced therapy medicinal products KW - mesenchymal stem and stromal cells KW - progressive supranuclear palsy KW - treatment options KW - adrenal medulla KW - stromal cells Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117594 VL - 12 IS - 14 ER -